Primer: Ono Pharmaceutical (4528 JP) - Aug 2026
Ono's financial performance is under significant pressure due to the continued sales decline of its flagship immuno-oncology drug, Opdivo, which...
100 Views
Primer: Ono Pharmaceutical (4528 JT) - Aug 2026
Ono Pharmaceutical's growth is fundamentally tied to its cornerstone immuno-oncology drug, Opdivo (nivolumab), which it co-develops with Bristol...
114 Views